Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft

Trial Profile

Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Cyclophosphamide; Fludarabine; Mycophenolate mofetil
  • Indications Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Paraproteinaemia; Plasma cell leukaemia; Polycythaemia vera; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2017 Planned number of patients changed from 60 to 120.
    • 11 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 11 Apr 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top